


Name:	Liu, Yao-Chung	Date: (YYYY/MM/DD):	2023 / 02 / 16	
Department:	Department of Hematology	Position:	Attending physician	
Email:	ycliu17@vghtpe.gov.tw	Contact #:	+886-2-28757529	
Education:	<ol style="list-style-type: none"> 2000 – 2007 M.D of Medicine of Chung Shan Medical University, Taichung, Taiwan 2016-2 – present Ongoing PhD program of Molecular Medicine Program, National Yang-Ming University OF Life Sciences 			
Experience:	<ul style="list-style-type: none"> ■ 2008/8-2011/8 Resident of Internal Medicine at Taipei Veterans General Hospital, Taiwan ■ 2011/8-2012/8 Chief Resident of Hematology and Oncology division at Taipei Veterans General Hospital, Taiwan ■ 2012/8-2013/8 Fellow of Hematology and Oncology division at Taipei Veterans General Hospital, Taiwan ■ 2013/9-2015/12 Attending physician of Hematology and Oncology division at Yang-Ming Branch of Taipei City Hospital, Taiwan ■ 2016/1-now Attending physician of Hematology division at Taipei Veterans General Hospital, Taiwan ■ 2018/8-2019/11 Visiting scholar in in Molecular Pathology & Oncology program, Boston, USA 			
Research Interests: (Key words)	Leukemia, Hypomethylating agents, SALL4, Siglec-7, Hematopoietic stem cell transplantation.			
Selected Publications (in recent 5 yr):	<ol style="list-style-type: none"> Liu YC, Kwon J, Fabiani E, et al. Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy. N Engl J Med. 2022 May 26;386(21):1998-2010. (2021 Impact factor: 176.079) Yang J, Gao C, Liu M, Liu YC, et al. Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy. Cancer Res. 2021 Dec 1;81(23):6018-6028. Liu YC, Su CW, Ko PS, et al. A clinical trial with valproic acid and hydralazine in combination with gemcitabine and cisplatin followed by doxorubicin and dacarbazine for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2022 Feb;18(1):19-27. Xu LH, Fang JP, Liu YC, et al. Nucleophosmin mutations confer an independent favorable prognostic impact in 869 pediatric patients with acute myeloid leukemia. Blood Cancer J. 2020 Jan 9;10(1):1. Liu YC, Wu CJ, Ko PS, et al. Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: A cohort study in a high endemic area. J Microbiol Immunol Infect. 2020 Apr;53(2):274-282. (2021 Impact factor: 10.273) 			

	<ol style="list-style-type: none"> 6. Liu YC, Chou YH, Ko PS, et al. Risk factors and clinical features for post-transplant thoracic air-leak syndrome in adult patients receiving allogeneic haematopoietic stem cell transplantation. Sci Rep. 2019 Aug 13;9(1):11795. 7. Lin TA, Gau JP, Liu YC**, et al. Cerebrovascular disease after allogeneic hematopoietic stem cell transplantation: incidence, risk, and clinical outcome. Int J Hematol. 2019 May;109(5):584-592. **:corresponding author 8. Chien SH, Liu YC, Liu CJ, et al. Invasive mold infections in acute leukemia patients undergoing allogeneic hematopoietic stem cell transplantation. J Microbiol Immunol Infect. 2019 Dec;52(6):973-982. (2021 Impact factor: 10.273) 9. Chen CT, Gau JP, Liu JH, Chiou TJ, Hsiao LT, Liu YC**. Early achievement of full donor chimerism after allogeneic hematopoietic stem cell transplantation predicts lower relapse risk in patients with acute lymphoblastic leukemia. J Chin Med Assoc. 2018 Dec;81(12):1038-1043. **:corresponding author 10. Chen YL, Liu YC (co-first), Wu CH, et al. Role of BMI and age in predicting pathologic vertebral fractures in newly diagnosed multiple myeloma patients: A retrospective cohort study. Hematol Oncol. 2018 Apr;36(2):407-415.
Names of Lab members:	Lin YT, Chao SC, Ko PS